Neoadjuvant Anlotinib and chemotherapy followed by minimally invasive esophagectomy in patients with locally advanced esophageal squamous cell carcinoma: Short-term results of an open-label, randomized, phase II trial

BACKGROUND: Clinical benefits of neoadjuvant Anlotinib for locally advanced esophageal squamous cell carcinoma (ESCC) remains unclear. This study evaluated the efficacy and safety of neoadjuvant Anlotinib plus chemotherapy followed by minimally invasive esophagectomy (MIE) for the treatment of patie...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Ying-Jian, Li, Kun-Kun, Xie, Xian-Feng, Bao, Tao, Hao, Zhi-Peng, Long, Jiang, Wang, Shuai, Zhong, Zhao-Yang, Guo, Wei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9380438/
https://www.ncbi.nlm.nih.gov/pubmed/35982957
http://dx.doi.org/10.3389/fonc.2022.908841

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9380438/
https://www.ncbi.nlm.nih.gov/pubmed/35982957
http://dx.doi.org/10.3389/fonc.2022.908841

Ejemplares similares